Enovis (ENOV) Short-term Investments (2017 - 2022)

Enovis (ENOV) posted quarterly Short-term Investments of $200.3 million for Q3 2022, down 23.87% quarter-over-quarter from $263.1 million in Q3 2022.

Enovis (ENOV) Short-term Investments (2017 - 2022) Analysis & Trends

Enovis (ENOV) has reported Short-term Investments for 2 consecutive years, with $200.3 million the latest figure, recorded in Q3 2022.

In Q3 2022, Short-term Investments changed N/A year-over-year to $200.3 million; the TTM figure through Sep 2022 stood at $200.3 million (changed N/A YoY), while the FY2017 annual figure was $149.6 million, changed N/A from the prior year.
Short-term Investments fell to $200.3 million in Q3 2022 per ENOV's latest filing, from $263.1 million in the prior quarter.
Across five years, Short-term Investments topped out at $263.1 million in Q3 2022 and bottomed at $200.3 million in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.07 Bn	193.46 Bn	7.27 Bn
2	Stryker	127.90 Bn	124.43 Bn	4.50 Bn
3	Medtronic	118.84 Bn	109.62 Bn	6.41 Bn
4	Boston Scientific	73.33 Bn	72.79 Bn	3.85 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn
6	Dexcom	34.46 Bn	32.51 Bn	830.00 Mn
7	GE HealthCare Technologies	33.91 Bn	31.81 Bn	2.18 Bn
8	Koninklijke Philips	26.36 Bn	23.04 Bn	4.55 Bn
9	Steris	23.12 Bn	22.64 Bn	684.20 Mn
10	Enovis	1.52 Bn	1.50 Bn	359.25 Mn

Download Data